Experienced in Bone Marrow Transplant

Dr. Nirmish R. Shah

Pediatrics | Hematology | Oncology
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Experienced in Bone Marrow Transplant
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nirmish Shah is a Pediatrics specialist and a Hematologist in Durham, North Carolina. Dr. Shah is rated as an Experienced provider by MediFind in Bone Marrow Transplant. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Shah is currently accepting new patients.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Bone Marrow Transplant.

Specialties
Pediatrics
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Enrollment Status: Terminated
Publish Date: December 31, 2025
Intervention Type: Drug
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
Enrollment Status: Completed
Publish Date: May 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Enrollment Status: Withdrawn
Publish Date: January 14, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
Use of a Mobile-based Pain Assessment Application for SCD Patients
Use of a Mobile-based Pain Assessment Application for SCD Patients
Enrollment Status: Completed
Publish Date: July 16, 2019
Use of Mobile Technology for Intensive Training in Medication Management
Use of Mobile Technology for Intensive Training in Medication Management
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 11 Less Clinical Trials

125 Total Publications

Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies.
Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies.
Journal: Blood reviews
Published: December 28, 2024
Similar Doctors
Distinguished in Bone Marrow Transplant
Dr. Nelson J. Chao
Oncology | Hematology
Distinguished in Bone Marrow Transplant
Dr. Nelson J. Chao
Oncology | Hematology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nelson Chao is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Chao is rated as a Distinguished provider by MediFind in Bone Marrow Transplant. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Multiple Myeloma, Bone Marrow Transplant, and Bone Graft. Dr. Chao is currently accepting new patients.

Distinguished in Bone Marrow Transplant
Dr. Katarzyna J. Jamieson
Hematology Oncology | Hematology | Oncology
Distinguished in Bone Marrow Transplant
Dr. Katarzyna J. Jamieson
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katarzyna Jamieson is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Jamieson is rated as an Advanced provider by MediFind in Bone Marrow Transplant. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jamieson is currently accepting new patients.

Advanced in Bone Marrow Transplant
Dr. Gwynn D. Long
Hematology Oncology | Hematology | Oncology
Advanced in Bone Marrow Transplant
Dr. Gwynn D. Long
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

234 Crooked Creek Pkwy, 
Durham, NC 
 (6.4 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gwynn Long is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Long is rated as a Distinguished provider by MediFind in Bone Marrow Transplant. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Colonoscopy. Dr. Long is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile